iLoF’s (intelligent Lab on Fiber) technology detects biomarkers of various neurodegenerative diseases, creating accurate optical ‘fingerprints’ representative of a patient’s phenotype and stage of disease. By improving efficiency to the screening and the stratifying of Alzheimer’s patients for clinical trials, iLoF contributes to finding a cure for the disease.
Former colleagues established that tiny biostructures found in the bloodstream of patients, called extracellular vesicles, are key predictors of how a disease can develop. I decided to combine photonics with Artificial Intelligence to find patterns in the light reflected by these vesicles, allowing us to map the information they carry.
Unique selling points
iLoF tackles a burning problem that hinders efforts in Alzheimer's treatment development. The non-invasive, portable, cheap technology will transform Alzheimer patient’s experience and make clinical trials convenient and patient-centric.
Forty-four million people live with Alzheimer’s disease, a number that is expected to triple by 2050. Over 400 clinical trials failed in past years, mostly due to patient drop out and unsuitability. iLoF hopes to successfully address this situation.
As a female PhD student, the challenge of translating innovative ideas in the academic environment was made even greater by the male-dominated environment of physics, engineering and computer science. A serial patented inventor with a passion for innovation, I focused on impact and ensuring that my technology would not end up on a shelf after the findings were published.